Not provided
Not provided
Not provided
Not provided
Not provided
lack of funding
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Diabetes Association | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Low testosterone production, known clinically as hypogonadism, appears to be common complication of type 2 diabetes, affecting one in three diabetic men. Hypogonadism is known to be associated with decreased muscle mass, increased fat mass, increased inflammation and decreased fertility. In this grant, the investigators propose to study the effects of having low testosterone on 1) insulin sensitivity, the ability of the body to handle glucose 2) fat and muscle mass at specific areas of the body 3) expression of mediators of inflammation in the blood 4) semen quality. This study will compare diabetic men (with or without hypogonadism). This study will also evaluate the effect of treatment with clomiphene (a drug that increases testosterone and sperm production) or testosterone in men with diabetes and hypogonadism. The investigators hope that this project will help us understand the state of hypogonadism in young type 2 diabetic men who are in their peak fertility years and give us insights into treatment of this condition. With the rising prevalence of type 2 diabetes in the young, this project may have implications for public health.
This project will study young men with type 2 diabetes. We have shown that half of these men have low testosterone levels. This can lead to 1) Low muscle mass; 2) more fat mass; 3) insulin resistance; 4) low sperm count and 5) increased inflammation (that increases the risk of heart disease). This project will study these consequences in detail and also the possibility of reversing them with treatment. Information from this project will be useful in planning of future studies that will evaluate the effect of treatment of low testosterone on mortality, heart disease and stroke.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| testosterone | Experimental | intramuscular injections every 2 weeks |
|
| clomiphene | Experimental | oral drug thrice a week |
|
| placebo for testosterone | Placebo Comparator | placebo for testosterone arm |
|
| placebo for clomiphene | Placebo Comparator | oral placebo for clomiphene arm |
|
| eugonadal obese | No Intervention | obese men with normal testosterone level | |
| lean | No Intervention | healthy lean men (control) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| testosterone | Drug | intramuscular every 2 weeks |
| |
| clomiphene |
| Measure | Description | Time Frame |
|---|---|---|
| Insulin Resistance | To compare the insulin sensitivity as measured by whole body glucose uptake during hyperinsulinemic euglycemic (HE) clamp in young T2D men with and without HH. | 6 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sandeep Dhindsa, MBBS | SUNY at Buffalo | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Millard Fillmore Gates Hospital | Buffalo | New York | 14209 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Testosterone | intramuscular injections every 2 weeks testosterone: intramuscular every 2 weeks |
| FG001 | Clomiphene | oral drug thrice a week clomiphene: thrice a week |
| FG002 | Placebo for Testosterone | placebo for testosterone arm placebo: intramuscular saline injections every 2 weeks |
| FG003 | Placebo for Clomiphene | oral placebo for clomiphene arm placebo: oral |
| FG004 | Eugonadal Obese | men with obesity and normal testosterone levels |
| FG005 | Control | lean healthy men with normal testosterone levels |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
no patients were recruited in 2 arms
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Testosterone | intramuscular injections every 2 weeks testosterone: intramuscular every 2 weeks |
| BG001 | Clomiphene | oral drug thrice a week clomiphene: thrice a week |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Insulin Resistance | To compare the insulin sensitivity as measured by whole body glucose uptake during hyperinsulinemic euglycemic (HE) clamp in young T2D men with and without HH. | study terminated | Posted | 6 months |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Testosterone | intramuscular injections every 2 weeks testosterone: intramuscular every 2 weeks |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| sandeep dhindsa | suny buffalo | sandhindsa@yahoo.com |
Not provided
| ID | Term |
|---|---|
| D007006 | Hypogonadism |
| D003924 | Diabetes Mellitus, Type 2 |
| D003920 | Diabetes Mellitus |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013739 | Testosterone |
| D002996 | Clomiphene |
| ID | Term |
|---|---|
| D000737 | Androstenols |
| D000736 | Androstenes |
| D000731 | Androstanes |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
thrice a week |
|
| placebo | Drug | intramuscular saline injections every 2 weeks |
|
| placebo | Drug | oral |
|
| BG002 | Placebo for Testosterone | placebo for testosterone arm placebo: intramuscular saline injections every 2 weeks |
| BG003 | Placebo for Clomiphene | oral placebo for clomiphene arm placebo: oral |
| BG004 | Eugonadal Obese | obese men with normal testosterone level |
| BG005 | Lean | healthy lean men (control) |
| BG006 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
placebo for testosterone arm
placebo: intramuscular saline injections every 2 weeks
| OG003 | Placebo for Clomiphene | oral placebo for clomiphene arm placebo: oral |
| OG004 | Eugonadal Obese | normal testosterone men |
| OG005 | Normal Lean | control |
|
| 0 |
| 1 |
| 0 |
| 1 |
| 0 |
| 1 |
| EG001 | Clomiphene | oral drug thrice a week clomiphene: thrice a week | 0 | 1 | 0 | 1 | 0 | 1 |
| EG002 | Placebo for Testosterone | placebo for testosterone arm placebo: intramuscular saline injections every 2 weeks | 0 | 0 | 0 | 0 | 0 | 0 |
| EG003 | Placebo for Clomiphene | oral placebo for clomiphene arm placebo: oral | 0 | 0 | 0 | 0 | 0 | 0 |
| EG004 | Eugonadal Obese | obese men with normal testosterone levels | 0 | 1 | 0 | 1 | 0 | 1 |
| EG005 | Control | healthy lean men with normal testosterone levels | 0 | 2 | 0 | 2 | 0 | 2 |
Not provided
Not provided
Not provided
| D009750 | Nutritional and Metabolic Diseases |
| D006946 | Hyperinsulinism |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D045165 | Testosterone Congeners |
| D012739 | Gonadal Steroid Hormones |
| D042341 | Gonadal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D013267 | Stilbenes |
| D001597 | Benzylidene Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |